Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?

Prostate Cancer and Prostatic Diseases, Published online: 01 September 2022; doi:10.1038/s41391-022-00585-8Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?

https://www.nature.com/articles/s41391-022-00585-8

Source: Prostate Cancer and Prostatic Diseases - September 1, 2022 Category: Urology & Nephrology Authors: Zachary Klaassen Lauren Howard Christopher J. D. Wallis Jessica L. Janes Amanda De Hoedt William J. Aronson Thomas J. Polascik Christopher J. Amling Christopher J. Kane Matthew R. Cooperberg Martha K. Terris Yuan Wu Stephen J. Freedland Source Type: research

More News: Cancer | Cancer & Oncology | Prostate Cancer | Urology & Nephrology

Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (&lt;9 months)?

Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?